Showing results (2501-2510 of 3,087) with videos related to

Sort By:
Pageof 309
Drug Safety|July 1, 2006
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular riskStephen P Motsko, Karen L Rascati, Anthony J Busti, et al.
Drug Safety|July 1, 2006
Safety of inhalation of a 50% nitrous oxide/oxygen premix: a prospective survey of 35 828 administrationsPeter Onody, Pascal Gil, Martine Hennequin
Drug Safety|June 27, 2022
Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety StudyRaphaelle Beau-Lejdstrom, Lai San Hong, Xabier Garcia de Albeniz, et al.
Drug Safety|December 17, 2022
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingCatherine B Johannes, Daniel C Beachler, J Bradley Layton, et al.
Drug Safety|December 14, 2022
Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort StudyJ Bradley Layton, Joan Forns, Lisa J McQuay, et al.
Drug Safety|January 19, 2023
Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant OutcomesAndrea K Chomistek, Kelesitse Phiri, Michael C Doherty, et al.
Drug Safety|December 30, 2022
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World SettingHeather E Danysh, Catherine B Johannes, Daniel C Beachler, et al.
Drug Safety|June 19, 2021
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in EudravigilanceAnnamaria Mascolo, Cristina Scavone, Carmen Ferrajolo, et al.
Drug Safety|July 5, 2021
Prevalence, Nature, Severity and Preventability of Adverse Drug Events in Mental Health Settings: Findings from the MedicAtion relateD harm in mEntal health hospitals (MADE) StudyGhadah H Alshehri, Darren M Ashcroft, Joanne Nguyen, et al.
Drug Safety|July 8, 2021
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort StudyVeena Hoffman, Jesper Hallas, Marie Linder, et al.
Pageof 309